Fundraising FoxHealthtech Startups
18,748 companies tagged Healthtech, with their investors and founders.
Bio Essence Corp is a US-based, publicly traded (OTC Pink: BIOE) biotechnology company that develops holistic wellness and supplement products and operates in-person clinics for patient care. It serves healthcare practitioners and patients, working with an in-house R&D team and a medical advisory board of healthcare professionals.
0 investors
Bio Usawa is a biotechnology company that develops and manufactures affordable monoclonal antibodies and biologic medicines, with a focus on bringing cancer and other therapies to patients in Africa and globally.
0 investors
Bio-Path Holdings is a clinical-stage biotechnology company developing antisense RNAi nanoparticle drugs as targeted, lower-toxicity cancer therapies for fragile patients ineligible for high-dose chemotherapy. Its pipeline targets blood cancers such as acute myeloid leukemia and lymphoma as well as solid tumors.
0 investors
0 investors
0 investors
BioCardia develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with a lead program targeting ischemic heart failure with reduced ejection fraction. Its work centers on autologous cell therapy delivered through clinical trials.
0 investors
0 investors
0 investors
The BioCollective develops microbiome research tools, including a whole-stool BioCollector Kit, a fecal sample bank, and the Bioflux computational metabolic model used to build and evaluate probiotic consortia. Its products and reference materials serve research institutions, biotherapeutics companies, and probiotic developers, and it also produces the BiotiQuest consumer probiotic brand.
0 investors
0 investors
BioCytics conducts translational cancer research, including a project with UNC Charlotte and Carolina BioOncology Institute to study the "dark genome" of cancer cells to identify sequences involved in tumor growth, immune response, and treatment response. Its work spans cell therapy, neoantigens, tumor infiltrating lymphocytes, and clinical research informatics.
0 investors
0 investors
Biodynamik is a medical device company developing orthopedic-driven regenerative technologies, including its XT3 System for treating diabetic foot ulcers. The company is pursuing U.S. clinical trials under FDA IDE approval.
0 investors
BioFactura is a clinical-stage biopharmaceutical company developing biologics and biosimilars, and has launched Capitol Biologics, a CDMO division offering contract development and manufacturing services to advance biologics from concept to clinic.
0 investors
0 investors
Biofrontera develops treatments for actinic keratosis and other common skin conditions, aimed at improving outcomes for dermatology patients and providers. The company operates in the pharmaceutical and dermatology space.
0 investors
Bioinsights offers an AI-powered platform that helps healthcare providers deliver functional, root-cause medicine by integrating symptom and biomarker analysis, treatment protocols, diagnostics, and fulfillment in one system. It serves a range of providers—including health coaches, nutritionists, physicians, and chiropractors—through tiered membership plans based on licensure.
0 investors
0 investors
0 investors
0 investors
Biome provides analytics tools for healthcare leaders, focused on improving cardiovascular care outcomes and reducing operational inefficiency. It serves hospitals and cardiac care centers, offering data-driven products including the Biome Performance Network for clinical and operational decision-making.
0 investors
0 investors
Biomerica develops diagnostic products for screening and detection of chronic medical conditions and cancers, offered as at-home tests, point-of-care solutions, and laboratory assays for healthcare providers and consumers.
0 investors
Bionano develops optical genome mapping (OGM) systems and analysis software that detect structural variants and chromosomal aberrations across the genome. Its tools serve clinical care, research, and therapeutics applications including hematological malignancies, solid tumors, reproductive health, rare disease, and cell line quality control.
0 investors